Comparative Pharmacology
Head-to-head clinical analysis: ERYC versus ERYTHROCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ERYC versus ERYTHROCIN.
ERYC vs ERYTHROCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin acts by binding to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation step.
Erythromycin is a macrolide antibiotic that binds to the 50S subunit of the bacterial ribosome, inhibiting protein synthesis by blocking translocation of peptidyl-tRNA. It also exhibits anti-inflammatory and prokinetic effects via motilin receptor agonism.
250-500 mg orally every 6 hours or 333-500 mg orally every 8 hours; maximum 4 g/day.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6 hours.
None Documented
None Documented
2–4 hours in adults with normal renal function; prolonged to 4–8 hours in severe hepatic impairment; does not significantly change in renal failure.
Terminal elimination half-life is approximately 1.5-2 hours in adults; may prolong to 4-6 hours in hepatic impairment or neonates.
Primarily biliary excretion of unchanged drug (60–80%); renal excretion accounts for 10–15% of an oral dose, with minimal fecal elimination (<5%).
Primarily eliminated via biliary excretion as unchanged drug and metabolites; approximately 2-5% excreted renally as active drug, 15-20% as metabolites; up to 30% excreted in feces.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic